Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia.

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Volume 119, Issue 4, Pages (April 2001)

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia Arman Hasani, MBBS, FRACP, John M. Alvarez,

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung.

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma Dean A. Fennell, PhD, FRCP,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up Marco Lucchi, MD, Franca Melfi, MD, Paolo.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

ALK FISH and IHC: You Cannot Have One without the Other

Epidemiology of Environmental Exposure and Malignant Mesothelioma

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma Valentina Pinelli, MD, Sophie.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

Electronic Updates for JTO Readers

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis María Uribarri, PhD, Itsaso Hormaeche, PhD, Rafael Zalacain, MD,

Diffusion-Weighted Magnetic Resonance Imaging for Diagnosing Malignant Pulmonary Nodules/Masses: Comparison with Positron Emission Tomography Takeshi.

John E. Pilling, FRCS (CTh), Michael E

An Unusual Presentation of Malignant Pleural Mesothelioma

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with.

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Frank Detterbeck, MD Journal of Thoracic Oncology

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease

ORAL SESSIONS Journal of Thoracic Oncology

MicroRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer Riccardo Cazzoli, PhD, Fiamma Buttitta,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Prospective Study on Functional Results After Lung-Sparing Radical Pleurectomy in the Management of Malignant Pleural Mesothelioma Servet Bölükbas, MD,

A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System Jie Lin, PhD, MPH, Corey A. Carter,

CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions Christophe Blanquart, PhD, Fabien Gueugnon, PhD, Jean-Michel.

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer Mohammad Chakra, MD, Jean Louis Pujol,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Surgical Treatment of Recurrent Thymomas

A Simple Solution for Complicated Pleural Effusions

MTP13-01: Indications and limitations of bronchoscopy

Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study Marcello Carlo Ambrogi,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

A Common Polymorphism Within MSLN Affects miR-611 Binding Site and Soluble Mesothelin Levels in Healthy People Sonia Garritano, PhD, Chiara De Santi,

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma Akihiro Yasumitsu, MD, Chiharu Tabata, MD, PhD, Rie.

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma Zacariah E. Labby, PhD, Samuel G. Armato, PhD,

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Silvia Bielsa, MD, José Martín-Juan, MD, José M

Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed.

International Thymic Malignancies Interest Group: A Way Forward

Linda L. Garland, MD, Kari Chansky, MS, Antoinette J

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed Steven Chuan-Hao Kao,

Combined Evaluation of Postoperative Serum Levels of Carcinoembryonic Antigen Less than or Equal to 2.5 ng/ml and Absence of Vascular Invasion may Predict.

Pleural Metastases of Malignant Melanoma

IASLC 6th Latin American Conference on Lung Cancer

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

Debby P. M. van den Bogaert, MD, Ellen M

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia Simonini, MD, Agnese Vivaldi, PhD, Giovanni Guglielmi, MD, Nicolino Ambrosino, MD, Antonio Chella, MD, Marco Lucchi, MD, Alfredo Mussi, MD, Rudy Foddis, MD Journal of Thoracic Oncology Volume 6, Issue 9, Pages 1587-1593 (September 2011) DOI: 10.1097/JTO.0b013e31821e1c08 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Plasma osteopontin (OPN) (A) and soluble mesothelin-related peptides (SMRP) (B) levels in healthy subjects, epithelial MPM patients, and BRD patients. MPM, malignant pleural mesothelioma; BRD, benign respiratory disease. Journal of Thoracic Oncology 2011 6, 1587-1593DOI: (10.1097/JTO.0b013e31821e1c08) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Receiver operating characteristic curves in case of predicted probability for pOPN, SMRP, and combination of pOPN and SMRP. The areas under the curves (AUCs) were determined for each marker, comparing healthy subjects and MPM patients. pOPN, plasma osteopontin; SMRP, soluble mesothelin-related peptides; MPM, malignant pleural mesothelioma. Journal of Thoracic Oncology 2011 6, 1587-1593DOI: (10.1097/JTO.0b013e31821e1c08) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 A, Plotted SMRP and pOPN concentrations in healthy subjects and BRD patients. The horizontal dotted line represents the best cutoff for pOPN (878.65 ng/ml) and the vertical dotted line for SMRP (1 nM). B, Linear regression between SMRP and pOPN levels in MPM patients. C, Linear regression between SMRP and pOPN levels in healthy controls and BRD patients. D, Linear regression between SMRP and pOPN levels in all study subjects. pOPN, plasma osteopontin; SMRP, soluble mesothelin-related peptides; BRD, benign respiratory disease. Journal of Thoracic Oncology 2011 6, 1587-1593DOI: (10.1097/JTO.0b013e31821e1c08) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions